874959-68-9

Basic information

• Product Name: 5-BROMO-PYRIDINE-2-SULFONYL CHLORIDE
• Synonyms: 5-BROMO-PYRIDINE-2-SULFONYL CHLORIDE;5-Bromo-2-pyridinesulfonyl chloride;2-Pyridinesulfonyl chloride, 5-bromo-
• CAS NO: 874959-68-9
• Molecular Formula: C₅H₃BrClNO₂S
• Molecular Weight: 256.5
• Mol File: 874959-68-9.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 301 °C at 760 mmHg
• Flash Point: 135.8 °C
• Appearance: /
• Density: 1.893 g/cm³
• Vapor Pressure: 0.00194mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Solubility: Chloroform (Slightly)
• PKA: -7.49±0.29(Predicted)
• Stability: Moisture Sensitive
• CAS DataBase Reference: 5-BROMO-PYRIDINE-2-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-PYRIDINE-2-SULFONYL CHLORIDE(874959-68-9)
• EPA Substance Registry System: 5-BROMO-PYRIDINE-2-SULFONYL CHLORIDE(874959-68-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 874959-68-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-pyridine-2-sulfonyl chloride is a chemical compound with the molecular formula C5H3BrN2O2SCl. It is a white to yellow solid that is primarily used as a reagent in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. 5-BROMO-PYRIDINE-2-SULFONYL CHLORIDE is a sulfonyl chloride derivative of 5-bromo-2-pyridine, and its reactive nature makes it useful for introducing the sulfonyl group into organic molecules. It is also a key building block for the synthesis of a variety of complex organic compounds, making it an important intermediate in the chemical industry. Additionally, it is known for its high reactivity and should be handled with care due to its potential to cause irritation or harm upon contact with skin and eyes.

InChI:InChI=1/C5H3BrClNO2S/c6-4-1-2-5(8-3-4)11(7,9)10/h1-3H

Upstream product

• 53939-30-3 5-bromo-2-chloropyridine 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 223463-13-6 2-iodo-5-bromopyridine 
• 56673-34-8 5-bromo-2-mercaptopyridine 
• 624-28-2 2,5-dibromopyridine 
• 874959-69-0 2-(benzylsulfanyl)-5-bromopyridine 

Downstream Products

• 1089669-82-8 C₂₄H₂₂F₂N₄O₆S₃ 
• 1272355-61-9 5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridine-2-sulfonamide 
• 19642-68-3 5-bromopyridine-2-sulfonamide 

Relevant articles and documents

N-LINKED GLYCOSYLATION INHIBITORS AND METHODS OF USING SAME

The present disclosure includes compounds, compositions, and methods for preventing or treating diseases associated with N-linked glycosylation and/or oligosaccharyltransferase function in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound and/or pharmaceutical composition of the disclosure.

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.

Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide

We have recently disclosed 5-phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine 1 as a potent IKur current blocker with selectivity versus hERG, Na and Ca channels, and an acceptable preclinical PK profile. Upon further characterization in vivo, compound 1 demonstrated an unacceptable level of brain penetration. In an effort to reduce the level of brain penetration while maintaining the overall profile, SAR was developed at the C2′ position for a series of close analogues by employing hydrogen bond donors. As a result, 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide (25) was identified as the lead compound in this series. Compound 25 showed robust effects in rabbit and canine pharmacodynamic models and an acceptable cross-species pharmacokinetic profile and was advanced as the clinical candidate. Further optimization of 25 to mitigate pH-dependent absorption resulted in identification of the corresponding phosphoramide prodrug (29) with an improved solubility and pharmacokinetic profile.